Treating pain amid the opioid epidemic: 4 Qs with Dr. Jerry Epps, CMO of UT Medical Center
Knox County, Tenn., home to University of Tennessee Medical Center, tallied 118 deaths related to opioid overdoses in the first seven months of 2016. As UTMC is positioned in an area of the country hard hit by the opioid epidemic, the hospital addresses patient pain in a unique fashion, emphasizing multimodal analgesics and protocols designed to identify drug dependence in patients.
Jerry Epps, MD, was named CMO of UT Medical Center in April. With a clinical focus on pediatric and cardiology anesthesia, Dr. Epps has been practicing anesthesia in the state of Tennessee for nearly 30 years. In that time, he's witnessed the rise of the opioid epidemic first hand. In 2014, opioid overdose deaths in Tennessee reached a record high of 1,263, according to the Tennessee Department of Health.
Recently Dr. Epps spoke with Becker's about pain treatment at UT Medical Center and issues pertaining to the opioid epidemic.
Note: Responses have been lightly edited for length and clarity.
Question: Has UT Medical Center experienced an increase in treating individuals suffering from opioid addiction?
Dr. Epps: Yes, there is no question. In Tennessee, we also have the problem of poor behavioral health services. So these services are a limited resource for our institution. We have patients who are in the thralls of drug abuse who do get help and are on a treatment plan to combat addiction with medications like buprenorphine, naloxone or Suboxone, a combination of the two. Only certain physicians are certified to prescribe those drugs, so we coordinate with the medical director of Cherokee Health [headquartered in Knoxville] because they have physicians with the certification to prescribe these medications. We also treat pregnant women who are on these medications, so we have to coordinate care across our two institutions.
Q: What role do you feel the patient's expectation of pain plays in the opioid epidemic? How does the Pain Management Pathway at UT Medical Center address patient expectations?
JE: Our pain pathways are both specific pathways for the patient and are also a standardization of procedures across the system. We start with assessing the baseline pain, or where the patient's pain starts when they come through the door. Assessment of baseline pain establishes the true goal of analgesic control in the hospital setting. We have an escalation process to address patient concerns, so for the patients who have chronic pain who don't feel that their pain is being addressed, we do have an outside source who can come in and conduct an evaluation. Also, our pain pathways encourage the use of nonnarcotic medication especially as it pertains to neuropathic pain, or chronic pain, pain is coming from the nerves themselves.
Historically we've always used a pain scale, in which patients rate their pain by numbers 1 to 10. The problem is a patient comes in the established pain was eight, the patient expects it to go to zero, the providers expectation is we are not going to get their chronic pain down to zero. We're trying to move away from the scale and focus instead on function. We can say to the patient "we want you to get up and walk after this procedure." We want to focus on a patient's functional ability and get the pain under control as opposed to just focusing on a number.
Built into our pathways are red flags designed to signal to nurses and caregivers when the cause of the pain is not being treated appropriately. If the pain is outside the expected location, if it is in excess or out of proportion for the type of injury, or if a nurse's intuition or gestalt is telling them something is off, then this will prompt a reexamination of the pain. An experienced nurse can tell something just is not right.
Q: The DEA recently reduced opioid manufacturing quotas by 25 percent. How helpful do you think recent actions taken by the federal government will be in curbing the rates of opioid abuse?
JE: It's really too little too late. If this had happened 10 to 15 years ago when the epidemic was surging, I might have a different answer. In 2013, the DEA allowed manufactures to increase opioid production by 25 percent because they thought there was going to be shortage. The new reduction still puts us above where we were in 2010 and 2012.
Tennessee Gov. Bill Haslam and his task force have greatly diminished the number of pills being prescribed [in Tennessee], but we're still seeing deaths. We know when the number of prescriptions diminishes, patients are switching to illicit drugs as opposed to illicitly obtained prescription narcotics. We're continuing to see high rates of heroin deaths and deaths due to narcotics being manufactured in other parts of the world. Fentanyl, the most commonly used pain control medication in surgery and anesthesia, is being manufactured in South America, Mexico and China. These fentanyl pills are designed to look like oxycodone and there have been a slate of deaths related to these drugs. Carefentil is being made to look like medication that resembles oxycodone. Carefentil was designed to be used to tranquilize large animals such as elephants and is extremely potent.
I don't think DEA's efforts are going to make that much difference at all.
Q: In your opinion, what is the future of pain management going to look like?
JE: The big difference now is identifying whether the patient has neuropathic pain or acute pain, and finding a way to incorporate multimodal nonnarcotic pain medication. The use of preemptive analgesia will continue to increase. This process can block the nerve impulse of pain from reaching the brain and the pain can be greatly diminished. We'll also see an increase in use of medications like gabapentin [a nerve pain medication] to treat neuropathic pain.
From the physician prescribing side, there's going to be even more attempts to make sure that the pills prescribed will be limited in number. We're seeing evidence that physicians are starting to decrease the number of pills prescribed. Pill mills are dramatically decreasing across the South.
If you would have asked us [physicians] in the past if a patient is given a limited number of pills, would that patient likely become addicted to narcotics after one procedure, most of us would have probably said no. Now we know a significant amount of people who are opioid naive who get one prescription of narcotics are still taking them a year later. That fact changes the physician perspective of treating pain with narcotics. Additionally, about half the people we prescribe narcotics to don't take the full prescription. When pills tend to lie around the house, improper use is more likely to occur.
On the cutting edge of things, we have what we described as pharmacogenetics. What we have recognized is that there are certain genes that predict addiction tendencies. Individuals reacted differently to medications. For example, codeine must be metabolized in the liver but 10 to 12 percent of Caucasians cannot metabolize it at all, which renders the medication ineffective. Now we can do a swab inside of your cheek and get your DNA and discover if you have addictive indicators in your DNA and how you process narcotics. Going forward, I imagine we will prescribe medicine based on individual DNA makeup.
More articles on quality:
44 hospitals with the lowest stroke death rates
6 hospitals in Pennsylvania with top nurse-patient communication scores
No hospital is perfect: Highly rated hospitals still rank low in certain procedures, FairChex finds
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.